Kavanagh B P, Pearl R G
Department of Anesthesia, Stanford University School of Medicine, California, USA.
Int Anesthesiol Clin. 1995 Winter;33(1):181-210.
Inhaled NO is an exciting new drug and has enormous potential in the therapy of a wide variety of acute, and possibly chronic, cardiopulmonary disorders. No reports of controlled, randomized, and blinded trials have been published concerning the use of inhaled NO in any clinical condition. In the United States, use of inhaled NO currently requires an investigational new drug approval from the Food and Drug Administration. Physicians involved in anesthesia and critical care medicine have a unique opportunity to validate a new mode of therapy in acute care, and optimal evaluation should be undertaken so that the real therapeutic role of inhaled NO may be defined.
吸入一氧化氮是一种令人兴奋的新型药物，在治疗各种急性乃至可能的慢性心肺疾病方面具有巨大潜力。目前尚无关于吸入一氧化氮在任何临床情况下使用的对照、随机和双盲试验报告。在美国，目前使用吸入一氧化氮需要获得食品药品监督管理局的新药研究批准。参与麻醉和重症医学的医生有独特的机会在急性护理中验证一种新的治疗模式，应进行最佳评估，以便确定吸入一氧化氮的真正治疗作用。
